These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 9462205)

  • 1. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole.
    Berstad AE; Hatlebakk JG; Maartmann-Moe H; Berstad A; Brandtzaeg P
    Gut; 1997 Dec; 41(6):740-7. PubMed ID: 9462205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients.
    Jhala NC; McFarland MM; Brightman SA; Morale B; Rubin W; Atkinson BF
    Am J Gastroenterol; 1995 Oct; 90(10):1824-8. PubMed ID: 7572902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Helicobacter pylori infection on gastric juice pH.
    Furuta T; Baba S; Takashima M; Futami H; Arai H; Kajimura M; Hanai H; Kaneko E
    Scand J Gastroenterol; 1998 Apr; 33(4):357-63. PubMed ID: 9605256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
    Gremse DA
    Expert Opin Pharmacother; 2001 Oct; 2(10):1663-70. PubMed ID: 11825309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.
    Eissele R; Brunner G; Simon B; Solcia E; Arnold R
    Gastroenterology; 1997 Mar; 112(3):707-17. PubMed ID: 9041231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa.
    Geboes K; Dekker W; Mulder CJ; Nusteling K;
    Aliment Pharmacol Ther; 2001 Nov; 15(11):1819-26. PubMed ID: 11683696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease.
    Meining A; Kiel G; Stolte M
    Aliment Pharmacol Ther; 1998 Aug; 12(8):735-40. PubMed ID: 9726386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease.
    Stolte M; Meining A; Schmitz JM; Alexandridis T; Seifert E
    Aliment Pharmacol Ther; 1998 Mar; 12(3):247-53. PubMed ID: 9570259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eradication therapy of Helicobacter pylori directly induces apoptosis in inflammation-related immunocytes in the gastric mucosa--possible mechanism for cure of peptic ulcer disease and MALT lymphoma with a low-grade malignancy.
    Ohara T; Kanoh Y; Higuchi K; Arakawa T; Morisita T
    Hepatogastroenterology; 2003; 50(51):607-9. PubMed ID: 12828043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan.
    Uemura N; Okamoto S; Yamamoto S; Matsumura N; Yamaguchi S; Mashiba H; Sasaki N; Taniyama K
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1345-52. PubMed ID: 11012481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.
    Kuipers EJ; Nelis GF; Klinkenberg-Knol EC; Snel P; Goldfain D; Kolkman JJ; Festen HP; Dent J; Zeitoun P; Havu N; Lamm M; Walan A
    Gut; 2004 Jan; 53(1):12-20. PubMed ID: 14684569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lansoprazole and Helicobacter pylori infection.
    Pallone F; Luzza F; Delle Fave G; Annibale B; Marcheggiano A; Biancone L; Torsoli A; Capurso L
    Clin Ther; 1993; 15 Suppl B():49-57. PubMed ID: 8205595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation.
    Cahill RJ; Xia H; Kilgallen C; Beattie S; Hamilton H; O'Morain C
    Dig Dis Sci; 1995 Aug; 40(8):1627-31. PubMed ID: 7648960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
    Hirschowitz BI; Haber MM
    Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression.
    Moayyedi P; Wason C; Peacock R; Walan A; Bardhan K; Axon AT; Dixon MF
    Helicobacter; 2000 Dec; 5(4):206-14. PubMed ID: 11179985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
    Suzuki M; Suzuki H; Kitahora T; Miyazawa M; Nagahashi S; Suzuki K; Ishii H
    Aliment Pharmacol Ther; 2002 Jan; 16(1):159-65. PubMed ID: 11856091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the effects of Helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective six-month follow-up study.
    Demiray M; Gulten M; Manavoglu O; Evrensel T; Ulukaya E; Yerci O; Kanat O; Kurt E; Arslan M; Gonullu G; Demiray H; Gulten T; Memik F
    Hepatogastroenterology; 2004; 51(59):1531-5. PubMed ID: 15362794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.